Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. JAK inhibitors and infections risk: focus on herpes zoster. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors. Segan J, Staples MP, March L, Lassere M, Chakravarty EF, Buchbinder R. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Herpes zoster and the risk of stroke in patients with autoimmune diseases. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: a post hoc analysis of data from a phase IIIb/IV randomized study. Complications of shingles.Ĭalabrese LH, Abud-Mendoza C, Lindsey SM, et al. Signs and symptoms of shingles (herpes zoster).Ĭenters for Disease Control and Prevention. doi:10.1136/annrheumdis-2021-220651Ĭenters for Disease Control and Prevention. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. doi:10.1002/acr2.11150Ĭenters for Disease Control and Prevention.
Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. Stevens E, Weinblatt ME, Massarotti E, Griffin F, Emani S, Desai S. Shingrix shingles vaccination: what everyone should know. Centers for Disease Control and Prevention.
0 kommentar(er)
